What's Happening?
CRISPR Therapeutics has provided an update on zugocabtagene geleucel (zugo-cel), its investigational allogeneic CAR T cell therapy, in a Phase 1 basket trial for refractory rheumatologic autoimmune diseases. The trial includes patients with systemic lupus
erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathy (IIM). As of October 15, 2026, 21 patients have been dosed across these cohorts: four with SLE, eight with SSc, and nine with IIM. Data presented at ACR Convergence 2026 showed promising results, particularly in SSc patients, where 83% (5/6) receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining their response. Additionally, all nine IIM patients achieved a moderate or major Total Improvement Score (TIS) response. The company reported that Zugo-cel was well tolerated across all 21 patients, with no cytokine release syndrome (CRS) above Grade 2 and no immune effector cell-associated neurotoxicity syndrome (ICANS) or hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).
Why It's Important?
This update is significant for patients suffering from severe, refractory autoimmune diseases like SLE, SSc, and IIM, which often have limited effective treatment options and can lead to significant morbidity and mortality. The positive early-phase data suggest that zugo-cel, a gene-edited allogeneic CAR T cell therapy, could offer a novel and effective therapeutic approach. The high response rates observed in SSc and IIM patients, coupled with a favorable safety profile (low incidence of severe CRS and absence of ICANS/IEC-HS), are particularly encouraging. Allogeneic therapies, which use cells from healthy donors, have the potential to be more readily available and less complex to manufacture than autologous therapies, making them more accessible to a broader patient population. If these positive trends continue in later-stage trials, zugo-cel could transform the treatment landscape for these debilitating autoimmune conditions, offering hope for improved disease control and quality of life.
What's Next?
CRISPR Therapeutics is continuing to evaluate zugo-cel in its ongoing Phase 1 basket trials. In addition to the rheumatology basket, zugo-cel is also being assessed in Phase 1 trials for autoimmune hematologic diseases and autoimmune neurologic diseases. Future steps will likely involve advancing zugo-cel into later-stage clinical trials (Phase 2 and 3) to further confirm its efficacy, safety, and optimal dosing regimens across a larger and more diverse patient population. The company will need to demonstrate sustained responses and long-term safety to gain regulatory approval. Continued monitoring for potential long-term side effects and immune responses to the allogeneic cells will also be crucial. The success of these trials could pave the way for regulatory submissions and eventual market availability, offering a new class of treatment for a range of severe autoimmune disorders.
Beyond the Headlines
The development of zugo-cel highlights the growing potential of gene-edited cell therapies beyond oncology, extending into the complex realm of autoimmune diseases. This represents a significant scientific and medical advancement, demonstrating the versatility of CRISPR technology. The use of allogeneic CAR T cells in autoimmune diseases could overcome some of the logistical and manufacturing challenges associated with autologous cell therapies, potentially making these advanced treatments more scalable and affordable. However, broader adoption will depend on demonstrating long-term durability of response and managing potential immune reactions against donor cells. Furthermore, the success of such therapies could spur further research into gene editing for other chronic inflammatory and immune-mediated conditions, opening new avenues for therapeutic intervention. The economic implications are also substantial, as effective treatments for chronic autoimmune diseases could reduce long-term healthcare burdens, but the initial cost of these advanced therapies will be a critical factor in their accessibility and integration into healthcare systems.
